Advertisement
Research Article

Attenuated T Cell Responses to a High-Potency Ligand In Vivo

  • Emily Corse,

    Affiliation: Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Rachel A. Gottschalk,

    Affiliations: Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, New York, United States of America

    X
  • Michelle Krogsgaard,

    Affiliation: Department of Pathology and New York University (NYU) Cancer Institute, NYU School of Medicine, New York, New York, United States of America

    X
  • James P. Allison mail

    allisonj@mskcc.org

    Affiliation: Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Published: September 14, 2010
  • DOI: 10.1371/journal.pbio.1000481

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

The Goldilocks Model for TCR—Too Much Attraction Might Not Be Best for Vaccine Design

Jill E. Slansky, Kimberly R. Jordan
Primer | published 14 Sep 2010 | PLOS Biology
doi:10.1371/journal.pbio.1000482